FINDING OF NO SIGNIFICANT IMPACT

Marketing Order for

Grizzly Premium Natural Fine Cut

Manufactured by American Snuff Company, LLC

The Center for Tobacco Products of the Food and Drug Administration (FDA) has carefully considered the potential environmental impacts of this action and has concluded that this action will not have significant effects on the quality of the human environment. Therefore, an environmental impact statements is not required.

American Snuff Company wishes to introduce a new loose moist snuff tobacco product into interstate commerce for commercial distribution in the United States and submitted to FDA a substantial equivalence report to obtain a marketing order under the provisions of sections 910 and 905(j) of the Federal Food, Drug, and Cosmetic Act.

The Agency prepared the environmental assessment (EA), dated April 20, 2020, in accordance with the Council on Environmental Quality's regulations (40 CFR 1500–1508) implementing the National Environmental Policy Act (NEPA) and FDA’s NEPA regulations (21 CFR 25.40) to support the finding of no significant impact. The evidence supporting this finding is contained in the attached EA, which is available to the public upon request.

The EA evaluates potential environmental effects due to manufacturing, use, and disposal of the new product. No increased or new types of environmental impacts due to manufacturing the new product are anticipated. The Agency does not foresee that use of the new product would result in new or different environmental impacts. The Agency believes that the disposal of the new product would be the same as the disposal conditions of similar smokeless tobacco products that are currently marketed in the United States. Therefore, the Agency does not foresee adverse impacts to the environment due to the proposed actions as a result of manufacturing, use, and disposal of the new product.

For Digitally signed by Luis G. Valerio -S
Date: 2020.04.21 09:15:04 -04'00'

Approved by
Kimberly Benson, Ph.D.
Director
Division of Nonclinical Science
Office of Science
Center for Tobacco Products
U.S. Food and Drug Administration